Bioanalytical automation: history and future plans
1994
Automating Bioanalysis: History and Future Plans
Sample size: 200000
publication
Evidence: moderate
Author Information
Author(s): Raymond H. Farmen
Primary Institution: Bristol-Myers Squibb
Hypothesis
Can the entire bioanalytical process be automated to improve efficiency and reduce costs?
Conclusion
Automating the bioanalytical process could significantly increase productivity and reduce costs while improving safety.
Supporting Evidence
- Automating the bioanalytical process could increase sample processing from 175 to 1500 samples per week per analyst.
- Bristol-Myers Squibb spent $2.4 million on bioanalytical contracts in 1992.
- The cost of automated bioanalysis could decrease to about $38 per sample as the number of samples increases.
- The automation laboratory is projected to require a staff of six bioanalytical scientists and other support roles.
Takeaway
This study talks about making the process of testing drugs in blood and urine much faster and safer by using robots to do the work instead of people.
Methodology
The paper discusses the rationale and plans for automating the bioanalytical process at Bristol-Myers Squibb.
Limitations
The automation plan is expensive and requires new technology development.
Want to read the original?
Access the complete publication on the publisher's website